Operating Segments (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) segment	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Segment reporting
Revenues	$ 206,929	$ 228,640	$ 464,107	$ 416,703
Income (loss) from Operations	(1,630,324)	(3,395,296)	(3,781,013)	(7,587,682)
Amortization and Depreciation Expense	1,590	8,512	3,375	16,744
Other (Expense) Income, Net	18,300	(146,399)	(38,317)	(303,034)
Share-Based Compensation	90,042	71,670	163,676	149,941
Identifiable Assets	13,826,253		$ 13,826,253		$ 14,279,717
Number of operating segments | segment			2
Operating Segments [Member] | Specialized BioTherapeutics [Member]
Segment reporting
Revenues	68,505		$ 223,870
Income (loss) from Operations	(611,300)	(2,000,350)	(1,521,677)	(3,540,078)
Amortization and Depreciation Expense	954	2,783	2,025	5,397
Other (Expense) Income, Net	9,931	68,509	16,013	123,588
Share-Based Compensation	27,427	28,343	54,854	56,847
Identifiable Assets	79,830		79,830		103,742
Operating Segments [Member] | Public Health Solutions [Member]
Segment reporting
Revenues	138,424	228,640	240,237	416,703
Income (loss) from Operations	(2,247)	(1,002)	(1,820)	(121,623)
Amortization and Depreciation Expense	159	463	337	899
Share-Based Compensation	994	1,054	1,988	2,108
Identifiable Assets	118,791		118,791		121,290
Corporate [Member]
Segment reporting
Income (loss) from Operations	(1,016,777)	(1,393,944)	(2,257,516)	(3,925,981)
Amortization and Depreciation Expense	477	5,266	1,013	10,448
Other (Expense) Income, Net	8,369	(214,908)	(54,330)	(426,622)
Share-Based Compensation	61,621	$ 42,273	106,834	$ 90,986
Identifiable Assets	$ 13,627,632		$ 13,627,632		$ 14,054,685